Biofrigas (BIOF) Q4 2025 earnings summary

Executive summary

• Achieved key operational milestones in Q4 2025, including first customer delivery and demonstration of biogas liquefaction technology.

• Focused on installation, market outreach, and scaling sales activities to secure new contracts.

• Strengthened financial position through successful options program, raising approximately 3 MSEK.

Financial highlights

• Q4 2025 net sales were KSEK 0, down from KSEK 2,304 in Q4 2024; full-year net sales were KSEK 275, down from KSEK 6,144.

• Q4 result after financial items was KSEK -2,970 (Q4 2024: -2,747); full-year result after financial items was KSEK -11,398 (2024: -9,738).

• Earnings per share for Q4 was -0.03 SEK (-0.05); full-year EPS was -0.12 SEK (-0.17).

• Solid equity ratio at 72.9% (72.7% in 2024).

• Year-end cash position was KSEK 2,178 (KSEK 8,239 in 2024).

Outlook and guidance

• 2026 focus on completing Habo commissioning, further developing CryoSep platform, and establishing more reference sites in Sweden and the Nordics.

• Plans to intensify sales activities and strategic partnerships to support commercialization and growth.